Male infertility treatment for cancer survivors: does anticancer treatment affect infertility treatment?
Adult
Antineoplastic Agents
/ administration & dosage
Cancer Survivors
/ statistics & numerical data
Costs and Cost Analysis
Cryopreservation
/ methods
Fertility Preservation
/ methods
Humans
Infertility, Male
/ diagnosis
Japan
/ epidemiology
Male
Needs Assessment
Neoplasms
/ drug therapy
Radiotherapy
/ adverse effects
Sperm Retrieval
/ economics
Spermatozoa
/ drug effects
ICSI outcome
anti-cancer treatment
cancer survivor
male infertility
sperm retrieval surgery
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
25
9
2021
Statut:
ppublish
Résumé
We investigated the impact of prior anticancer treatments such as chemotherapy and radiotherapy on subsequent infertility treatment in cancer survivors who consulted our male infertility division. Of 1,525 male infertility patients who consulted our division between 2008 and 2018, 56 (3.7%) were cancer survivors. Of these, 32 received anticancer treatment (group A) and 24 were treated with surgery alone or were seen before anticancer treatment (group B). Semen analysis revealed that azoospermia in 26 subjects (81.3%) and 14 (58.3%) in groups A and B respectively. Ejaculatory dysfunction was observed 1 in group A and in 2 group B subjects. Sperm cryopreservation before anticancer treatment was performed 4 subjects. Sperm retrieval surgery for intracytoplasmic sperm injection (ICSI) was performed in 13 cases in group A and 10 in group B. Motile sperm were recovered in 7 subjects and in 8 subjects in group A and B respectively. Overall pregnancies and deliveries with ICSI were achieved for 7 subjects (21.9%) in group A, and 9 (37.5%) in group B. Successful sperm retrieval may not be affected by prior anticancer treatment as shown in this study. However, some patients abandoned infertility treatment due to the cost of testing and sperm retrieval surgery. Support for the cost of infertility treatment in cancer survivors is necessary.
Identifiants
pubmed: 33311798
doi: 10.18999/nagjms.82.4.677
pmc: PMC7719443
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-684Déclaration de conflit d'intérêts
Each author has no COI with regard to this manuscript.
Références
Hum Reprod Update. 2001 Jul-Aug;7(4):370-7
pubmed: 11476349
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Hum Reprod. 1999 Jan;14(1):131-5
pubmed: 10374109
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Reprod Med Biol. 2008 Aug 03;7(3):115-118
pubmed: 29699291
J Natl Cancer Inst Monogr. 2005;(34):12-7
pubmed: 15784814
Reprod Biomed Online. 2016 Feb;32(2):147-53
pubmed: 26687904
Cell Prolif. 2012 Apr;45(2):91-100
pubmed: 22324506
Hum Genet. 1990 Oct;85(5):495-9
pubmed: 2227933
Reprod Med Biol. 2017 Jul 07;16(4):320-324
pubmed: 29259484
Reprod Med Biol. 2017 Oct 31;17(1):59-63
pubmed: 29371822
Cancer Treat Rev. 2007 Nov;33(7):646-55
pubmed: 17499440
Arch Androl. 2007 Mar-Apr;53(2):63-5
pubmed: 17453682
Int J Urol. 2010 Apr;17(4):327-31
pubmed: 20202000
Int J Cancer. 2010 Mar 1;126(5):1196-205
pubmed: 19728329